ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Merck Provides Update on Multiple Myeloma Studies of KEYTRUDA® in Combination with Other Therapies
June 14, 2017Merck has provided an update on two combination studies of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in the blood cancer multiple myeloma. Merck has accepted the external Data Monitoring Committee recommendation to pause new enrollment o
Pharma Sources Insight January 2025
